{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T09:42:13Z","timestamp":1694857333604},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"48","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>Abstract<\/jats:title>\n            <jats:p>The aim of this study was to evaluate the cost-effectiveness of Anbainuo (ABN) plus methotrexate (MTX) (ABN\u200a+\u200aMTX) versus conventional disease-modifying anti-rheumatic drugs (cDMARDs) in rheumatoid arthritis (RA) patients.<\/jats:p>\n            <jats:p>Forty-eight moderate to severe RA patients underwent ABN\u200a+\u200aMTX or cDMARDs treatment were consecutively enrolled and assigned to ABN\u200a+\u200aMTX group (n\u200a=\u200a26) and control group (n\u200a=\u200a22). Patients were followed up and their disease activity and quality of life (QoL) were evaluated at 3rd month, 6th month and 12th month after initiation of treatment. Treatment costs of 2 groups were calculated, then pharmacoeconomic analysis was performed.<\/jats:p>\n            <jats:p>ABN\u200a+\u200aMTX increased drug cost and total cost while decreased indirect cost compared with cDMARDs after 12-month treatment. ABN\u200a+\u200aMTX group gained additional 0.22 quality-adjusted life years (QALY) and yielded an incremental cost-effectiveness ratio (ICER) of \u00a5104,293.6 per QALY after treatment. Sensitivity analysis reveals that rising ABN price by 20% produced an ICER of \u00a5130,403.6 per QALY, which was still lower than 3 times of the mean gross domestic product (GDP) per capita during the same period in China (\u00a5165,960). Besides, ABN\u200a+\u200aMTX was more cost-effective in severe RA patients compared to moderate RA patients.<\/jats:p>\n            <jats:p>ABN\u200a+\u200aMTX is cost-effective in treating moderate to severe RA patients compared with cDMARDs, although the total cost of ABN\u200a+\u200aMTX is relatively higher.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000017750","type":"journal-article","created":{"date-parts":[[2019,11,26]],"date-time":"2019-11-26T19:58:55Z","timestamp":1574798335000},"page":"e17750","source":"Crossref","is-referenced-by-count":2,"title":["A novel etanercept biosimilar Anbainuo plus methotrexate exhibits increased cost-effectiveness compared to conventional disease-modifying anti-rheumatic drugs in treating rheumatoid arthritis patients"],"prefix":"10.1097","volume":"98","author":[{"given":"Feng","family":"Tian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing-Yang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhen-Hua","family":"Wen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-Wen","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing-Yun","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2019,11]]},"reference":[{"key":"R1-20230915","first-page":"242","article-title":"2018 Chinese guideline for the diagnosis and treatment of rheumatoid arthritis","volume":"57","author":"Chinese Rheumatology","year":"2018","journal-title":"Zhonghua Nei Ke Za Zhi"},{"key":"R2-20230915","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1016\/S0140-6736(17)31472-1","article-title":"Pathogenetic insights from the treatment of rheumatoid arthritis","volume":"389","author":"McInnes","year":"2017","journal-title":"Lancet"},{"key":"R3-20230915","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","article-title":"Rheumatoid arthritis","volume":"388","author":"Smolen","year":"2016","journal-title":"Lancet"},{"key":"R4-20230915","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1016\/S0140-6736(17)31491-5","article-title":"Novel treatment strategies in rheumatoid arthritis","volume":"389","author":"Burmester","year":"2017","journal-title":"Lancet"},{"key":"R5-20230915","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/nri.2016.124","article-title":"The immunopathogenesis of seropositive rheumatoid arthritis: from triggering to targeting","volume":"17","author":"Malmstrom","year":"2017","journal-title":"Nat Rev Immunol"},{"key":"R6-20230915","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1038\/nm.2050","article-title":"Synovial fibroblasts spread rheumatoid arthritis to unaffected joints","volume":"15","author":"Lefevre","year":"2009","journal-title":"Nat Med"},{"key":"R7-20230915","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/nri2804","article-title":"The changing face of rheumatoid arthritis: sustained remission for all?","volume":"10","author":"Isaacs","year":"2010","journal-title":"Nat Rev Immunol"},{"key":"R8-20230915","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1093\/rheumatology\/kem115","article-title":"Modelling the cost effectiveness of TNF-alpha antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry","volume":"46","author":"Brennan","year":"2007","journal-title":"Rheumatology"},{"key":"R9-20230915","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1093\/rheumatology\/keg451","article-title":"Modelling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK","volume":"43","author":"Brennan","year":"2004","journal-title":"Rheumatology"},{"key":"R10-20230915","doi-asserted-by":"crossref","first-page":"340","DOI":"10.3111\/13696998.2011.649327","article-title":"Cost-effectiveness of adalimumab, etanercept, and tocilizumab as first-line treatments for moderate-to-severe rheumatoid arthritis","volume":"15","author":"Soini","year":"2012","journal-title":"J Med Econ"},{"key":"R11-20230915","doi-asserted-by":"crossref","first-page":"8","DOI":"10.7326\/M16-0713","article-title":"Triple therapy versus biologic therapy for active rheumatoid arthritis: a cost-effectiveness analysis","volume":"167","author":"Bansback","year":"2017","journal-title":"Ann Inter Med"},{"key":"R12-20230915","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1002\/acr.22895","article-title":"Cost-effectiveness of triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis","volume":"68","author":"Jalal","year":"2016","journal-title":"Arthr Care Res"},{"key":"R13-20230915","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s10067-012-2096-z","article-title":"A multicenter, randomized, double-blind clinical trial of combination therapy with Anbainuo, a novel recombinant human TNFRII:Fc fusion protein, plus methotrexate versus methotrexate alone or Anbainuo alone in Chinese patients with moderate to severe rheumatoid arthritis","volume":"32","author":"Chen","year":"2013","journal-title":"Clin Rheumatol"},{"key":"R14-20230915","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1007\/s10067-016-3302-1","article-title":"A randomized, controlled trial of efficacy and safety of Anbainuo, a bio-similar etanercept, for moderate to severe rheumatoid arthritis inadequately responding to methotrexate","volume":"35","author":"Chen","year":"2016","journal-title":"Clin Rheumatol"},{"key":"R16-20230915","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jval.2010.11.001","article-title":"Using HAQ-DI to estimate HUI-3 and EQ-5D utility values for patients with rheumatoid arthritis in Spain","volume":"14","author":"Carreno","year":"2011","journal-title":"Value Health"},{"key":"R17-20230915","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1136\/heartjnl-2015-308255","article-title":"QALYs in cost-effectiveness analysis: an overview for cardiologists","volume":"101","author":"Wouters","year":"2015","journal-title":"Heart"},{"key":"R18-20230915","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3899\/jrheum.080257","article-title":"Cost-effectiveness of sequential therapy with tumor necrosis factor antagonists in early rheumatoid arthritis","volume":"36","author":"Davies","year":"2009","journal-title":"Journal Rheumatol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000017750","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T22:41:52Z","timestamp":1694817712000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000017750"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":17,"journal-issue":{"issue":"48","published-online":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000017750","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11]]}}}